Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
07
12
2020
accepted:
18
03
2021
entrez:
22
5
2021
pubmed:
23
5
2021
medline:
22
1
2022
Statut:
epublish
Résumé
To compare the real-world effectiveness of newer disease-modifying therapies (DMTs) vs injectables in children with relapsing-remitting multiple sclerosis (RRMS). In this retrospective, multicenter study, from the UK Childhood Inflammatory Demyelination Network, we identified children with RRMS receiving DMTs from January 2012 to December 2018. Clinical and paraclinical data were retrieved from the medical records. Annualized relapse rates (ARRs) before and on treatment, time to relapse, time to new MRI lesions, and change in Expanded Disability Status Scale (EDSS) score were calculated. Of 103 children treated with DMTs, followed up for 3.8 years, relapses on treatment were recorded in 53/89 (59.5%) on injectables vs 8/54 (15%) on newer DMTs. The ARR was reduced from 1.9 to 1.1 on injectables ( Newer DMTs were associated with a lower risk of clinical and radiologic relapses in patients compared with injectables. Our study adds weight to the argument for an imminent shift in practice toward the use of newer, more efficacious DMTs in the first instance. This study provides Class IV evidence that newer DMTs (oral or infusions) are superior to injectables (interferon beta/glatiramer acetate) in reducing both clinical relapses and radiologic activity in children with RRMS.
Identifiants
pubmed: 34021056
pii: 8/4/e1008
doi: 10.1212/NXI.0000000000001008
pmc: PMC8143699
pii:
doi:
Substances chimiques
Immunomodulating Agents
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : MR/T024437/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Curr Opin Neurol. 2018 Jun;31(3):233-243
pubmed: 29634596
Mult Scler. 2020 Jul 7;:1352458520937644
pubmed: 32633605
Ann Neurol. 2020 Jul;88(1):42-55
pubmed: 32267005
Neurology. 2016 Aug 30;87(9 Suppl 2):S74-81
pubmed: 27572865
N Engl J Med. 2007 Jun 21;356(25):2603-13
pubmed: 17582070
J Neurol Neurosurg Psychiatry. 2020 Jan;91(1):58-66
pubmed: 31467033
Arch Neurol. 2009 Aug;66(8):967-71
pubmed: 19667217
J Neurol Neurosurg Psychiatry. 2020 May;91(5):483-492
pubmed: 32132224
Neurology. 2008 May 13;70(20):1891-7
pubmed: 18474844
Lancet Neurol. 2015 Mar;14(3):302-17
pubmed: 25662900
Mult Scler. 2019 Jun;25(7):927-936
pubmed: 30945587
Neurology. 2016 Aug 30;87(9 Suppl 2):S97-S102
pubmed: 27572869
Arch Neurol. 2009 Jan;66(1):54-9
pubmed: 19139299
Neurology. 2019 Apr 9;92(15):e1709-e1723
pubmed: 30867274
JAMA. 2019 Jan 15;321(2):175-187
pubmed: 30644981
Brain. 2015 Jul;138(Pt 7):1863-74
pubmed: 25902415
Neurology. 2002 Dec 24;59(12):1922-8
pubmed: 12499484
Mult Scler Relat Disord. 2014 Nov;3(6):689-95
pubmed: 25798373
Mult Scler. 2019 Jan;25(1):72-80
pubmed: 28933245
Brain. 2020 Sep 1;143(9):2733-2741
pubmed: 32810215
JAMA Neurol. 2019 Sep 1;76(9):1028-1034
pubmed: 31206130
N Engl J Med. 2018 Sep 13;379(11):1017-1027
pubmed: 30207920
Lancet Neurol. 2014 Sep;13(9):936-48
pubmed: 25142460
Neurology. 2014 Dec 2;83(23):2140-6
pubmed: 25378667
Mult Scler. 2016 Mar;22(3):354-61
pubmed: 26041802
Mult Scler. 2018 Feb;24(2):175-185
pubmed: 28273780
Dev Med Child Neurol. 2019 Sep;61(9):1039-1049
pubmed: 30932181
Dev Neuropsychol. 2007;32(2):625-44
pubmed: 17931122